Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo + ICIs in ALK-rearranged NSCLC Progressed After Alectinib
NCT04997382Phase 2Completed
- Sponsor
- Hunan Cancer Hospital
- Start
- Aug 2021
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Started Aug 2021; status: completed.
02
Drugs
pembrolizumabatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04997382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04997382.